- Home
- CHRS vs VIRC Comparison
CHRS vs VIRC Comparison
Compare CHRS & VIRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- VIRC
- Stock Information
- Founded
- CHRS 2010
- VIRC 1950
- Country
- CHRS United States
- VIRC United States
- Employees
- CHRS N/A
- VIRC N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- VIRC Industrial Specialties
- Sector
- CHRS Health Care
- VIRC Consumer Discretionary
- Exchange
- CHRS Nasdaq
- VIRC Nasdaq
- Market Cap
- CHRS 191.3M
- VIRC 176.7M
- IPO Year
- CHRS 2014
- VIRC N/A
- Fundamental
- Price
- CHRS $1.47
- VIRC $9.30
- Analyst Decision
- CHRS Strong Buy
- VIRC Buy
- Analyst Count
- CHRS 4
- VIRC 1
- Target Price
- CHRS $5.38
- VIRC $19.00
- AVG Volume (30 Days)
- CHRS 2.3M
- VIRC 173.3K
- Earning Date
- CHRS 11-06-2024
- VIRC 12-09-2024
- Dividend Yield
- CHRS N/A
- VIRC 0.97%
- EPS Growth
- CHRS N/A
- VIRC N/A
- EPS
- CHRS N/A
- VIRC 1.53
- Revenue
- CHRS $304,340,000.00
- VIRC $280,375,000.00
- Revenue This Year
- CHRS $2.47
- VIRC $6.43
- Revenue Next Year
- CHRS N/A
- VIRC $2.38
- P/E Ratio
- CHRS N/A
- VIRC $6.08
- Revenue Growth
- CHRS 44.19
- VIRC 5.68
- 52 Week Low
- CHRS $0.66
- VIRC $8.75
- 52 Week High
- CHRS $2.97
- VIRC $18.50
- Technical
- Relative Strength Index (RSI)
- CHRS 50.55
- VIRC 20.61
- Support Level
- CHRS $1.35
- VIRC $10.09
- Resistance Level
- CHRS $1.77
- VIRC $10.45
- Average True Range (ATR)
- CHRS 0.13
- VIRC 0.36
- MACD
- CHRS -0.02
- VIRC 0.01
- Stochastic Oscillator
- CHRS 28.57
- VIRC 12.09
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About VIRC Virco Manufacturing Corporation
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, and activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.